Abstract

We report a metabolomic analysis of Streptomyces sp. ID38640, a soil isolate that produces the bacterial RNA polymerase inhibitor pseudouridimycin. The analysis was performed on the wild type, on three newly constructed and seven previously reported mutant strains disabled in different genes required for pseudouridimycin biosynthesis. The results indicate that Streptomyces sp. ID38640 is able to produce, in addition to lydicamycins and deferroxiamines, as previously reported, also the lassopeptide ulleungdin, the non-ribosomal peptide antipain and the osmoprotectant ectoine. The corresponding biosynthetic gene clusters were readily identified in the strain genome. We also detected the known compound pyridindolol, for which we propose a previously unreported biosynthetic gene cluster, as well as three families of unknown metabolites. Remarkably, the levels of most metabolites varied strongly in the different mutant strains, an observation that enabled detection of metabolites unnoticed in the wild type. Systematic investigation of the accumulated metabolites in the ten different pum mutants identified shed further light on pseudouridimycin biosynthesis. We also show that several Streptomyces strains, able to produce pseudouridimycin, have distinct genetic relationship and metabolic profile with ID38640.

Highlights

  • We report a metabolomic analysis of Streptomyces sp

  • The pseudouridine synthase PumJ catalyzes N- to C-nucleoside isomerization to yield pseudouridine or a derivative thereof, which is converted into 5′-amino-5′-deoxy pseudourydine (APU) by the action of the oxidoreductase PumI and the aminotransferase PumG

  • Each strain was cultivated in two media and we analyzed the metabolite distribution by liquid chromatography (LC)–mass spectrometry (MS) at 24-h intervals over four days

Read more

Summary

Introduction

We report a metabolomic analysis of Streptomyces sp. ID38640, a soil isolate that produces the bacterial RNA polymerase inhibitor pseudouridimycin. The analysis was performed on the wild type, on three newly constructed and seven previously reported mutant strains disabled in different genes required for pseudouridimycin biosynthesis. Different methods have been explored to define and harness this biosynthetic potential, including cultivating strains in the presence of elicitors or stress s­ ubstances[6,7], modifying BGC p­ romoters[8], manipulating BGC specific r­ egulators[9] and deploying decoys of BGC r­ epressors[10]. In all these approaches, the detection of secondary metabolites heavily relies on liquid chromatography (LC) coupled to mass spectrometry (MS).

Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call